We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Dap4.4

Dapagliflozin Research

Mostly mechanism / observational

795 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Dapagliflozin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 2009–2026 with a typical study size of 238 participants.

Based on 795 studies · 214 meta-analyses · 531 RCTs · 131,798 total participants

Confidence

High confidence

By outcome

Cardiovascular & heart failureDAPA-HF and DELIVER reduced cardiovascular death and heart-failure hospitalization across the full ejection-fraction spectrum, including in non-diabetics · Months to years
Mostly mechanism / observational375 studies
Aging & healthspan (emerging)
Mostly mechanism / observational30 studies
Safety profile
Mostly mechanism / observational19 studies

Active research area

517 studies in the last 5 years · Latest meta-analysis: 2026

200920172026

1Meta-Analysis2026

Xu B, Liu Y, He Z, Zhou J · J Endocrinol Invest (2026)

Dapagliflozin Research

Mostly mechanism / observational

Association between SGLT2 inhibitors and genital cancer: a meta-analysis and mendelian randomization study.

Meta-analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH).

Safety Profile of SGLT-2 Inhibitors in Older Adults: A Systematic Review and Network Meta-Analysis.

The Effects of SGLT2 Inhibitors on Muscle Health in Older Adults: A Systematic Review and Meta-Analysis.

The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis.

Effects of dapagliflozin on mortality across the spectrum of cardiovascular-kidney-metabolic syndrome: a meta-analysis.

Efficacy of Dapagliflozin in the Treatment of Type 2 Diabetes Mellitus Complicated by Coronary Heart Disease: A Meta-Analysis.

Efficacy and Safety of Pioglitazone Add-On in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Efficacy of dapagliflozin to treat nonalcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis.

Hypouricemic effect of sodium glucose transporter-2 inhibitors: a network meta-analysis and meta-regression of randomized clinical trials.

Dapagliflozin combined with methylcobalamin in the treatment of type 2 diabetes mellitus with peripheral neuropathy: a systematic review and meta-analysis.

Long-term effect of sodium-glucose cotransporter 2 inhibitors in kidney functions: A systematic review and meta-analysis.

Redefining treatment paradigms: Early use of dapagliflozin and empagliflozin in acute heart failure - a systematic review and meta-analysis of randomized controlled trials.

Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in heart failure patients: a meta-analysis of randomized controlled trials.

Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 Trials.

Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis.

Efficacy & safety of sodium-glucose cotransporter-2 inhibitors in polycystic ovary syndrome: A meta-analysis with trial sequential analysis.

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Nervous System Disorders: A Systematic Review and Meta-Analysis.

The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis.

Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease.